Results 31 to 40 of about 14,063,199 (303)

Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes [PDF]

open access: yes, 2006
Background: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host ...
Wagner, Thomas   +17 more
core   +2 more sources

Early-stage and mature B lymphocytes significantly decreased but long-lived B lymphocytes increased in APRIL-/-/BLyS-/- group.

open access: yes, 2022
Flow cytometry was used to assess B lymphocytes for each transplant group. Each graph shows number of cells per 100,000 lymphocytes. A-/-/B-/-, APRIL-/-/BLyS-/-. Data analyzed using ANOVA.
Natalie M. Bath (6316517)   +7 more
core   +1 more source

Lymphocytes [PDF]

open access: yes, 2019
Lymphocytes have been the main research object of the medic and toxicological sciences for the last six decades. In addition to important roles, they ply m the immune system, lymphocytes have been the primary test material often employed m pure research ...
İla, Hasan Basri
core   +1 more source

Subpopulations of B lymphocytes in patients with breast cancer depending on the PD-L1 status

open access: yesБюллетень сибирской медицины, 2023
Aim. To study the association between the functional potency and degree of maturity of B lymphocytes and PD-L1 expression in breast cancer patients.Materials and methods.
L. A. Tashireva   +4 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA

open access: yesНаучно-практическая ревматология, 2013
Objective: to study the efficiency and tolerance of rituximab (RTM) treatment in patients with scleroderma systematica (SDS) with interstitial lung injury (ILI).Subjects and methods. The trial included 27 patients (26 women and 1 man) (mean age 45.7±13.0
Lidia Petrovna Ananieva   +10 more
doaj   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

On adaptor proteins shaping Ca2+ signals in activated B lymphocytes [PDF]

open access: yes, 2008
Neumann K. On adaptor proteins shaping Ca2+ signals in activated B lymphocytes. Bielefeld (Germany): Bielefeld University; 2008.Signale des B-Zell-Antigenrezeptors (BZR) regeln sowohl die Aktivierung pathogenspezifischer B-Lymphozyten als auch die ...
Neumann, Konstantin
core  

microRNAs in the control of lymphocytes response [PDF]

open access: yes, 2009
Recently, it has become evident the importance of miRNAs in regulating immune response, as well as immune cell development. During my phD fellow I focused my attention on the relationship B-lymphocytes-microRNA; in particular I examined two the different
Rossi, Annalisa
core   +1 more source

Studying the effect of double-stranded RNA upon activity of mouse splenocytes using flow cytometry

open access: yesМедицинская иммунология, 2023
Ribonucleic acids (RNA), in particular, double-stranded RNAs, due to their ability to modulate innate immune responses, are of undoubted interest in view of their usage as vaccine adjuvants.
E. S. Tsyplenkova   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy